Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 23, 2008

GTC Secures U.S. Partner to Advance Drug Targeted at Antithrombin Deficiencies

  •  Ovation Pharmaceuticals has signed on to assist with the development and marketing of GTC Biotherapeutics’ ATryn® in the U.S. The agreement includes $257 million in potential payments to GTC for meeting clinical, regulatory, and sales milestones. 

    The collaboration is initially focused on development and commercialization of ATryn for hereditary antithrombin deficiency (HD). The milestone payments include a total of $9 million through approval of ATryn for HD in the U.S., including $3 million paid upon closing and an additional $2 million expected this year. The collaboration also plans for further development in antithrombin deficiencies such as the treatment of heparin resistance in patients undergoing surgery requiring cardiopulmonary bypass and the treatment of disseminated intravascular coagulation associated with severe sepsis.

    GTC will be responsible for production of ATryn and will receive a transfer price on commercial product, a royalty on net sales, and a payment for product used in clinical trials. As the collaboration proceeds, Ovation will fund GTC’s anticipated costs of clinical development. Ovation will be responsible for sales and marketing of ATryn in the U.S., including all launch activities.

    ATryn, a recombinant form of human antithrombin, has already been granted both Orphan Drug designation and Fast Track status for HD. It has also been approved for use in the EU for HD patients undergoing surgical procedures. LEO Pharma is responsible for commercializing and developing ATryn in Europe.


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »